Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels.The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.Business verticals:Domestic Sales & Merchant Exports (Loan License Basis)– contributing 96.62% of total revenue in FY 2024-25.Direct Exports– Contributing 38%, showing consistent growth.It has a manufacturing facility in Gujarat covers about 10,763 sq. ft., equipped with modern infrastructure, including 13 air handling units, separate processing areas, and quality control systems. The facility is GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certified, with an FSSAI license.Competitive StrengthsExperienced promoters and management TeamDiverse product portfolioCommitment to quality standardsRelationships with clients and suppliersEstablished business process and management framework
| Category | Shares Offered* | Total Amt* (₹ Cr.) |
|---|---|---|
|
Anchor
|
96,000 | ₹1.240 |
|
QIB (Ex Anchor)
|
908,000 | ₹11.710 |
|
NII
|
276,000 | ₹3.560 |
|
Retail
|
640,000 | ₹8.260 |
| Total ** | 1,920,000 | ₹24.770 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 2,000 | ₹258,000 |
| Retail (Max — 13 Lots) | 13 | 13,000 | ₹1,677,000 |
| S-HNI (Min — 14 Lots) | 14 | 14,000 | ₹1,806,000 |
| S-HNI (Max — 66 Lots) | 66 | 66,000 | ₹8,514,000 |
| B-HNI (Min — 67 Lots) | 67 | 67,000 | ₹8,643,000 |
| Category | QIB | NII | Retail | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor Investor | Total QIB | Below ₹10L | Above ₹10L | Total NII | |||
| Allocation (No. of shares) | — | — | — | — | — | 276,000 | 640,000 | 916,000 |
| Allotment price (Rs.) | 129 | 129 | 129 | 129 | 129 | 129 | 129 | 129 |
| No. of applications | — | — | — | — | — | — | — | — |
| No. of shares applied | — | — | — | — | — | — | — | — |
| Amount collected (Rs.cr.) | 11.71 | 1.24 | 12.95 | — | — | 3.56 | 8.26 | 24.77 |
| No. of times subscribed | — | — | — | — | — | — | — | — |
| No. of shares allotted | — | — | — | — | — | 276,000 | 640,000 | 916,000 |
| Amount (Rs.cr.) | 11.71 | 1.24 | 12.95 | — | — | 3.56 | 8.26 | 11.82 |
| No. of allottees | — | — | — | — | — | — | — | — |
| Category | Shares Offered | Amt (₹ Cr) | Size (%) |
|---|---|---|---|
| Anchor / Market Maker | 96,000 | ₹1.24 |
5.00%
|
| QIB (Ex Anchor) | 908,000 | ₹11.71 |
47.29%
|
| NII / HNI | 276,000 | ₹3.56 |
14.37%
|
| Retail (RII) | 640,000 | ₹8.26 |
33.33%
|
| Total | 1,920,000 | ₹24.77 |
100.00%
|
| Particulars | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue from Operations | 14.07 | 16.06 | 5.20 |
| EBITDA | 3.29 | 3.65 | 1.21 |
| Profit After Tax (PAT) | 2.33 | 2.61 | 0.82 |
| Net Worth | 8.26 | 5.35 | 1.08 |
| Total Assets | 16.35 | 10.86 | 4.64 |
| Reserves & Surplus | 2.95 | 4.86 | 0.72 |
| Total Borrowings | 4.43 | 3.86 | 2.17 |
| EBITDA Margin (%) | 23.36 | — | — |
| PAT Margin (%) | 16.59 | — | — |
Accretion Nutraveda Ltd proposes to utilize the net proceeds raised through this IPO for the following objects as stated in the Draft Red Herring Prospectus (DRHP) filed with SEBI: